Study of CD388 for the Prevention of Influenza in Subjects Not at Risk for Influenza Complications

Inclusion criteria

• ✓. Willing and able to provide written informed consent and comply with scheduled visits, laboratory tests, and other study procedures.
• ✓. Males and females 18 to less than 64 years of age.
• ✓. In the Investigator's clinical judgment, is in stable health at the time of screening and randomization. Participants may not have underlying hematologic, oncologic, renal, autoimmune, and/or cardiopulmonary illnesses or be considered at risk of developing complications from influenza infection per the CDC guidelines (chronic obstructive pulmonary disease \[COPD\], asthma, immune compromised current cancer \[except non-melanomatous skin cancer\], or diabetes). Subjects will be included on the basis of medical history and vital signs taken between signing of the informed consent and randomization.
• ✓. Body mass index (BMI; calculated as weight in kilograms \[kg\] divided by height in meters \[m\] squared) of 18.0 kg/m\^2 to 35.0 kg/m\^2 (inclusive).
• ✓. Women of childbearing potential (WOCBP) must:
• ✓. Have a negative pregnancy test (beta-human chorionic gonadotropin \[β-hCG\]) at screening, AND
• ✓. Be practicing a highly effective, preferably user-independent method of contraception (failure rate of less than 1 percent per year when used consistently and correctly) from ≥2 weeks prior to randomization and agrees to remain on a highly effective method from Day 1 until 32 weeks after study drug administration, the end of relevant systemic exposure. The Investigator should evaluate the potential for contraceptive method failure (e.g., noncompliance, recently initiated) in relationship to the day of administration of study drug.
• ✓. Female participants must agree not to donate or freeze eggs (ova, oocytes) for future use for the purposes of assisted reproduction from Day 1 until 32 weeks after study drug administration.

Exclusion criteria